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Abstract
The development and administration of mRNA vaccines
against SARS-CoV-2 are seeing lower numbers of COVID-19
cases and fatalities among fully vaccinated, immunocompetent adults. We present a case of fatal COVID-19 pneumonia

in a heart transplant recipient who had received two doses
of mRNA COVID-19 vaccine before the Centers for Disease
Control and Prevention had recommended additional doses.

Introduction

in mild respiratory distress, with otherwise unremarkable physical examination. Laboratory exams were significant for lymphopenia, with an absolute lymphocyte count of 500/µL and acute kidney injury (AKI),
with a serum creatinine of 3.0 mg/dL. Procalcitonin
level was 0.17 ng/mL. His brain natriuretic peptide
(BNP) level was found to be elevated at 235 pg/mL.
A chest X-ray showed cardiomegaly with pulmonary
vascular engorgement (Figure 1), and an electrocardiogram showed an atrial-sensed, ventricular-paced
rhythm with a ventricular rate of 86 beats/minute
(Figure 2).

In healthy individuals, exogenous mRNA such as that used
in the BNT162b vaccine stimulates strong induction of potent
inflammatory cytokines, which
elicit T- and B-cell-mediated immune responses.[1] An
interim analysis of the phase III trial showed that the
BNT162b vaccine conferred 95% protection against infection in persons 16 years of age or older who had received a two-dose regimen.[2] However, key exclusion
criteria for this study included a history of treatment
with immunosuppressive therapy or diagnosis with an
immunocompromising condition.[2] Although the vaccine is safe, data on its efficacy in transplant recipients
are mixed and are a topic of ongoing clinical investigation.
See editorial
commentary on this
article.

Case Description
A 71-year-old male presented with two days’ shortness of breath, myalgias, and chills in March 2021, before the Centers for Disease Control and Prevention
(CDC) had recommended third and fourth doses of the
mRNA vaccine. Vital signs on admission included a
temperature of 99.0 °F, heart rate of 108 beats/minute,
blood pressure of 137/86 mmHg, respiratory rate of 17
breaths/minute, and oxygen saturation ranging from
88 to 96% on 3L O2 through nasal cannula. He was
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The patient had received two doses of the COVID-19
vaccine four weeks apart, with the second dose 16 days
prior to admission.
Medical history
The patient received an orthotopic heart transplant
in 2008, with his most recent endomyocardial biopsy
in March 2016 (5 years prior to current presentation)
showing an International Society for Heart & Lung
Transplantation scale score of 0R. This biopsy, eight
years after the transplant, was performed to rule out
rejection because the patient was experiencing shortness of breath and fatigue at the time. Multiple
other biopsies in the past were unremarkable. He
also had a history of obesity (body mass index [BMI]
46.2), hypertension, unprovoked deep vein thrombosis, and dual chamber pacemaker implantation for
1
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Figure 1. Chest X-ray on admission showing cardiomegaly with pulmonary vascular engorgement.

Figure 2. Electrocardiogram on admission showing an atrial-sensed, ventricular-paced rhythm.
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Figure 3. Chest computed tomography showing left lower lobe atelectasis.

symptomatic bradycardia. The pacemaker implant was
likely related to loss of sympathetic tone of his transplanted heart, and unfortunately, additional details related to his history of symptomatic bradycardia are unknown. His home medications included mycophenolate mofetil 1,250 mg PO BID and tacrolimus 2 mg PO
daily for immunosuppression, amlodipine 5 mg, lisinopril 40 mg, and warfarin 7 mg daily.
Differential diagnosis included COVID-19 pneumonia,
other viral pneumonia, pulmonary embolus, acute bacterial pneumonia, transplant rejection, and heart failure
exacerbation.
Investigations

and ferritin, were within normal limits.
Further investigations revealed a therapeutic
tacrolimus level of 6.8 ng/mL (reference range 5–20
ng/mL). A computed tomography (CT) scan of the
chest with contrast showed bilateral lower lobe atelectasis with scattered reactive mediastinal and hilar lymph nodes without pleural effusions or endobronchial lesions and no pulmonary emboli (Figure
3). The patient had a gradual decline in the ejection
fraction of his transplanted heart over years, with a
two-dimensional echo on admission showing an ejection fraction of 45–50% and no major valve disease
(unchanged from previous echo one year prior).
Management

A nasopharyngeal swab was positive for SARS-CoV2 on admission. Initial infectious workup, including
nasopharyngeal swab for methicillin-resistant Staphylococcus aureus, viral respiratory panel, and urine studies for Streptococcus pneumoniae and legionella antigens,
was negative. High-sensitivity C-reactive protein was
elevated at 18.43 mg/L (reference range 0–4 mg/L).
Interleukin-6 levels were markedly elevated at 301.16
pg/mL (reference range <5 pg/mL). Other markers of
inflammation, such as lactate dehydrogenase, D-dimer,
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In light of a borderline normal ejection fraction of 45–
50%, which was stable over the last year, and only
marginally elevated BNP on admission, neither graft
dysfunction nor heart failure exacerbation was thought
to be a significant contributor to the patient’s illness.
Additionally, the patient’s vital signs (mild tachycardia thought to be from acute COVID-19 infection and
borderline elevated blood pressure) pointed away from
cardiogenic shock and need for mechanical circulatory
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Figure 4. Repeat chest X-ray on day 5 showing new and worsening pulmonary edema and possible multifocal pneumonia.

support.
The patient was started on dexamethasone (6 mg IV
daily) and remdesevir (200 mg as a single dose IV on
day 1, followed by 100 mg IV daily) for acute hypoxic
respiratory failure from COVID-19 pneumonia. All
his immunosuppressive medications were continued
on admission, and his tacrolimus dose was adjusted to
maintain therapeutic serum levels. The patient’s AKI
improved with fluid resuscitation, and he was subsequently started on enoxaparin 0.5 mg/kg subcutaneous BID.
Serial chest X-rays showed new and worsening pulmonary edema and possible multifocal pneumonia
(Figure 4). IV fluids were stopped, and the patient
was diuresed using bumetanide (2 mg IV BID). The
patient refused intubation and other advanced and invasive therapies, including renal replacement therapy.
Inhaled epoprostenol was not tried in this patient as
he presented in March 2021, when the role of inhaled
prostacyclin analogues in COVID-19-associated acute
respiratory distress syndrome (ARDS) was still being
explored and there were no data on the mortality benefit of these drugs in COVID-19 patients, which is a subject of ongoing studies. Given active immunosuppression, the patient was started on broad-spectrum antibiotic coverage with linezolid (600 mg IV Q12H) and cefepime (2 g IV Q8H). Fungal cultures, including histoplasma and aspergillosis, were negative. The patient
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continued to develop progressive dyspnea with hypoxia. We decided to start treatment with tocilizumab
(8 mg/kg IV single dose) for worsening COVID-19
pneumonia. IgG and IgM antibodies against SARSCoV-2 were tested to check for immune response to
the BNT162b vaccine and returned negative, suggesting absence of immunity against COVID-19 infection.
Follow-up
Over the course of 18 days, the patient’s respiratory status significantly worsened despite being on a high flow
nasal cannula with intermittent bilevel positive airway
pressure (BiPAP). The patient again declined intubation, opting for comfort measures instead, and expired
within a few hours.

Discussion
While the exact process of mRNA vaccine recognition by cellular sensors and the mechanism of sensor activation are still not clear [1], two kinds of RNA
sensors—endosomal toll-like receptors and the RIG-Ilike receptor family—have been identified. Tacrolimus
inhibits calcineurin, which is involved in the production of interleukin-2, a molecule that promotes the development and proliferation of T-lymphocytes.[3] Mycophenolate depletes guanosine nucleotides preferentially in T- and B-lymphocytes and inhibits their proliferation, thereby suppressing cell-mediated immune
4
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responses and antibody formation.[4] Both these drugs
are an important part of the traditional maintenance
immunosuppressive regimen for patients who undergo
orthotopic heart transplant.[3, 5] While the efficacy of
the COVID-19 vaccine in immunosuppressed patients
continues to be studied, it is likely that suppression
of cell-mediated immunity in transplant recipients impedes their ability to mount an appropriate immune response despite being able to detect the mRNA through
intracellular RNA sensors, thereby limiting protection
against COVID-19 infection in this population. There
are reports of interleukin-6 inhibitors, such as clazakizumab, that have been successfully used to treat
COVID-19 pneumonia in heart transplant recipients.[6]
Our patient received tocilizumab, an interleukin-6 receptor antagonist, but unfortunately did not respond
well to it, perhaps because of the severity of his illness and the extremely elevated level of interleukin6 on admission, which is predictive of poor outcomes
in COVID-19 infection.[7, 8] The use of convalescent
plasma is no longer recommended by the COVID-19

Treatment Guidelines Panel [9]; however, data on its
use in immunosuppressed patients are mixed.[9, 10]

Received: December 15, 2021

distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.

Accepted: May 3, 2022

Conclusions
We present a case of severe acute respiratory distress
syndrome due to SARS-CoV-2 that developed in a heart
transplant recipient on immunosuppression who had
received two doses of an mRNA COVID-19 vaccine.
Although the BNT162b vaccine is safe, data on its efficacy in transplant recipients are mixed. All immunocompromised patients should be encouraged to receive
the booster dose of COVID-19 vaccine per CDC guidelines.[11] Further, the American Society of Transplantation and the International Society for Heart & Lung
Transplantation jointly recommend third and fourth
doses of the BNT162b vaccine in this patient population.[12] An early and aggressive treatment strategy
should be considered in immunosuppressed patients
with even mild or moderate COVID-19 infection, irrespective of vaccination status.
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